The Wockhardt Group, formerly a prominent player in the pharmaceutical industry, is facing monumental distress. With mounting debts and a struggling business, the group's valuable assets are now headed to market. This unexpected development has sent shockwaves through the industry, raising eyebrows among analysts. It remains to be seen who will ul